Multi-institutional review of adverse events associated with irreversible electroporation in the treatment of locally advanced pancreatic cancer

Stephens, Kyle; Philips, Prejesh P.; Egger, Michael E.; Scoggins, Charles R.; McMasters, Kelly M.; Martin, Robert C.G.

doi:10.1016/j.surg.2023.08.042

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IRE has been extensively studied over the past years as a promising therapy for inoperable or advanced metastatic cancers affecting different organs, including the prostate [ 17 , 18 ], pancreas [ 19 , 20 ], liver [ 21 , 22 ] and breast [ 23 ]. Notably, preclinical studies have elucidated critical operational features, such as the need for neuromuscular blocking to decrease the muscle contractions caused by electrical stimulation and ECG synchronization to avert the induction of cardiac arrhythmias.…”

Section: Translational Use Of Ep In Veterinary Oncology and Humansmentioning

confidence: 99%

Electroporation in Translational Medicine: From Veterinary Experience to Human Oncology

Spugnini,

Condello,

Crispi

et al. 2024

Cancers

View full text Add to dashboard Cite

Electroporation (EP) is a broadly accepted procedure that, through the application of electric pulses with appropriate amplitudes and waveforms, promotes the delivery of anticancer molecules in various oncology therapies. EP considerably boosts the absorptivity of targeted cells to anticancer molecules of different natures, thus upgrading their effectiveness. Its use in veterinary oncology has been widely explored, and some applications, such as electrochemotherapy (ECT), are currently approved as first-line treatments for several neoplastic conditions. Other applications include irreversible electroporation and EP-based cancer vaccines. In human oncology, EP is still mostly restricted to therapies for cutaneous tumors and the palliation of cutaneous and visceral metastases of malignant tumors. Fields where veterinary experience could help smooth the clinical transition to humans include intraoperative EP, interventional medicine and cancer vaccines. This article recapitulates the state of the art of EP in veterinary and human oncology, recounting the most relevant results to date.

show abstract

Section: Translational Use Of Ep In Veterinary Oncology and Humansmentioning

confidence: 99%

Electroporation in Translational Medicine: From Veterinary Experience to Human Oncology

Spugnini,

Condello,

Crispi

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

Effectiveness and Safety of Irreversible Electroporation When Used for the Ablation of Stage 3 Pancreatic Adenocarcinoma: Initial Results from the DIRECT Registry Study

Martin,

White,

Bilimoria

et al. 2024

Cancers

View full text Add to dashboard Cite

Background/Objectives: Overall survival for patients with Stage 3 pancreatic ductal adenocarcinoma (PDAC) remains limited, with a median survival of 12 to 15 months. Irreversible electroporation (IRE) is a local tumor ablation method that induces cancerous cell death by disrupting cell membrane homeostasis. The DIRECT Registry study was designed to assess the effectiveness and safety of IRE when combined with standard of care (SOC) treatment for Stage 3 PDAC versus SOC alone in a real-world setting after at least 3 months of induction chemotherapy; Methods: Patients with Stage 3 PDAC treated with IRE plus SOC or SOC alone were prospectively enrolled in a multicenter registry study. Enrollment required 3 months of active multi-agent chemotherapy with no progression before enrollment. Endpoints were 30- and 90-day mortality and adverse events (AEs). Results: Eighty-seven IRE and 27 SOC subjects were enrolled in the registry. Mean ages were 64.0 ± 8.4 and 66.4 ± 9.9 years, and mean anterior/posterior tumor diameters were 2.2 ± 0.7 cm and 3.2 ± 1.3 for the IRE and SOC groups respectively (p = 0.0066). All IRE procedures were performed using an open approach. The 90-day all-cause mortality was 5/83 (6.0%) and 2/27 (7.4%) for the IRE and SOC groups, respectively. Two subjects in the IRE group died from treatment-related complications, and one patient in the SOC group died due to chemotherapy-related complications. Conclusions: Initial results from the DIRECT registry study indicate the use of IRE for curative intent tumor ablation in combination with induction chemotherapy has equivalent morbidity and mortality rates when compared to standard-of-care chemotherapy alone.

show abstract

Multi-institutional review of adverse events associated with irreversible electroporation in the treatment of locally advanced pancreatic cancer

Cited by 2 publications

References 32 publications

Electroporation in Translational Medicine: From Veterinary Experience to Human Oncology

Electroporation in Translational Medicine: From Veterinary Experience to Human Oncology

Effectiveness and Safety of Irreversible Electroporation When Used for the Ablation of Stage 3 Pancreatic Adenocarcinoma: Initial Results from the DIRECT Registry Study

Contact Info

Product

Resources

About